Microbiome Milestones: From Market Launch to Future Trends
Panel discussion summary
Join us for a dynamic session featuring a panel discussion followed by an exciting pitching segment. Experts, investors, and biotech leaders will explore key achievements, challenges, and success factors in microbiome-based therapies. Gain valuable insights into the future of microbiome research and healthcare. Afterwards, innovative companies will present their cutting-edge solutions to a jury of experts.
Date, time and room information
May 5, 15:30-16:15, room Rio
Moderation
| Name | Position | Institution |
|---|---|---|
| Tomas de Wouters | CEO | PharmaBiome |
Panelists
| Name | Position | Institution |
|---|---|---|
| Per Falk | CEO | GC Holdings |
| Isabelle de Cremoux | CEO | Seventure |
| Johanna Eliasson Vinterberg | Medical Director, Gastroenterology Therapeutic Area | Ferring Pharmaceuticals |
| Jonathan Chriqui | Chief Business Officer | Maat Pharma |
PharmaBiome AG & IQVIA AG
PharmaBiome has developed the leading microbiome drug-development platform for the design and production at scale of targeted microbiome therapeutics.
IQVIA is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry.
